Cardinal Health, Inc. $CAH Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC trimmed its position in shares of Cardinal Health, Inc. (NYSE:CAH) by 26.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,883 shares of the company’s stock after selling 3,972 shares during the period. TD Private Client Wealth LLC’s holdings in Cardinal Health were worth $1,708,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Counterpoint Mutual Funds LLC acquired a new stake in shares of Cardinal Health during the 2nd quarter worth about $1,911,000. Baird Financial Group Inc. increased its stake in shares of Cardinal Health by 107.2% in the second quarter. Baird Financial Group Inc. now owns 99,393 shares of the company’s stock valued at $16,698,000 after buying an additional 51,416 shares in the last quarter. Nomura Holdings Inc. lifted its position in Cardinal Health by 568.0% during the 2nd quarter. Nomura Holdings Inc. now owns 85,293 shares of the company’s stock worth $14,329,000 after buying an additional 72,525 shares in the last quarter. Voya Investment Management LLC grew its holdings in Cardinal Health by 298.3% during the 3rd quarter. Voya Investment Management LLC now owns 821,723 shares of the company’s stock worth $128,978,000 after acquiring an additional 615,398 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in Cardinal Health by 19.1% during the 2nd quarter. Marshall Wace LLP now owns 1,930,967 shares of the company’s stock worth $324,402,000 after acquiring an additional 309,335 shares during the last quarter. Institutional investors own 87.17% of the company’s stock.

Cardinal Health Stock Up 2.5%

Shares of CAH stock opened at $213.54 on Thursday. Cardinal Health, Inc. has a 12-month low of $120.72 and a 12-month high of $214.93. The firm has a fifty day moving average of $204.88 and a 200-day moving average of $174.05. The company has a market capitalization of $50.74 billion, a price-to-earnings ratio of 32.21, a P/E/G ratio of 1.52 and a beta of 0.65.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings results on Thursday, October 30th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.33. The company had revenue of $64.01 billion for the quarter, compared to analyst estimates of $59.41 billion. Cardinal Health had a negative return on equity of 84.37% and a net margin of 0.68%.The company’s quarterly revenue was up 22.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.88 earnings per share. Cardinal Health has set its FY 2026 guidance at 9.650-9.850 EPS. On average, equities analysts expect that Cardinal Health, Inc. will post 7.95 EPS for the current year.

Cardinal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Friday, January 2nd will be given a $0.5107 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, January 2nd. Cardinal Health’s payout ratio is currently 30.77%.

Cardinal Health News Roundup

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Raised FY‑2026 guidance to at least $10.00 non‑GAAP EPS (up from $9.65–$9.85), improving consensus beat probability and supporting earnings upside. Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation
• Positive Sentiment: Company now expects Specialty revenue to exceed $50 billion in FY‑2026 (roughly 16% CAGR over three years), signaling a faster mix shift to higher‑margin specialty distribution. Cardinal Health Stock Jumps on Guidance Raise. Why 2026 Will Be a Good Year.
• Positive Sentiment: Launched ContinuCare™ Pathway (direct‑to‑patient at‑home diabetes supply program) and announced a key partnership with Publix — a strategic push into services/retail that supports recurring revenue and patient stickiness. Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation
• Positive Sentiment: Management said it successfully transitioned manufacturer distribution service agreements affected by 2026 Medicare drug‑price negotiations, removing a key operational/legal overhang. Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation
• Positive Sentiment: Analysts have reacted with upgrades and higher fair‑value views after the guidance/strategy update, which can lift sentiment and support multiple expansion. Will Analyst Upgrades and Specialty Focus Change Cardinal Health’s (CAH) Healthcare Supply Chain Narrative?
• Neutral Sentiment: Management presentation materials and transcript from the J.P. Morgan Healthcare Conference provide detail on strategy execution and were posted for investor review. Review the slides/transcript for revenue cadence and margin assumptions. Cardinal Health, Inc. (CAH) Presents at 44th Annual J.P. Morgan Healthcare Conference – Slideshow Cardinal Health, Inc. (CAH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Market writeups note the stock’s intraday strength following the update; investors should watch upcoming earnings cadence vs. the new guidance and specialty margin realization. Why the Market Dipped But Cardinal Health (CAH) Gained Today
• Neutral Sentiment: Valuation/technical context: CAH is trading well above its 200‑day moving average with a P/E near 32 and PEG ~1.5 — investors should weigh growth acceleration vs. current multiple. How The Story For Cardinal Health (CAH) Is Shifting In Analysts Fair Value Views

Wall Street Analysts Forecast Growth

CAH has been the topic of several research analyst reports. Robert W. Baird set a $250.00 price target on shares of Cardinal Health in a research note on Wednesday. Leerink Partners set a $240.00 target price on Cardinal Health in a research report on Tuesday. TD Cowen increased their target price on Cardinal Health from $183.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Wall Street Zen upgraded Cardinal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Argus increased their price target on shares of Cardinal Health from $189.00 to $211.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $215.27.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.